Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | HPGD | P15428 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | TP53 | P04637 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.88 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.88 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.88 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | TTR | P02766 | 7/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163801 | 0.93 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL29627447 | 0.93 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL10453911 | 0.93 | KDM4E (0.90) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL10454176 | 0.92 | KDM4E (0.88) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL10454177 | 0.92 | KDM4E (0.88) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| Xanoxic Acid SCHEMBL29400285 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL11768660 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL11768887 | 0.86 | KMT2A (0.67) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL10785566 | 0.86 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL1105126 | 0.86 | KDM4E (0.73) | ALDH1A1KDM4EHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0028410-B1 | USE OF THROMBOXANE-SYNTHETASE INHIBITING COMPOUNDS IN THE TREATMENT OF OBESITY AND THE LOWERING OF INSULIN LEVELS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-30 | — | — | EP | claimed |
| EP-0028410-A1 | Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-05-13 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| CN-102149282-B | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2014-12-17 | — | — | CN | disclosed |
| US-4626432-A | 7-HYDROXY-OR ALKOXYXANTHONE-2-CARBOXYLIC ACID | BURROUGHS WELLCOME CO. (US) | 1986-12-02 | — | — | US | disclosed |
| US-4591594-A | INSULIN LOWERING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0028410-A1 | Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-05-13 | — | — | EP | disclosed |
| EP-0028410-A1 | Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-05-13 | — | — | EP | disclosed |